BidaskClub downgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a sell rating in a research report released on Friday, BidAskClub reports.

A number of other analysts have also recently commented on the stock. Stifel Nicolaus set a $99.00 price objective on shares of C.H. Robinson Worldwide and gave the company a hold rating in a research report on Monday, March 25th. Gabelli upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, March 25th. ValuEngine cut shares of Wolverine World Wide from a hold rating to a sell rating in a research report on Monday, May 20th. Wedbush set a $175.00 target price on shares of Lululemon Athletica and gave the stock a hold rating in a research note on Tuesday, June 11th. Finally, Zacks Investment Research raised shares of HB Fuller from a sell rating to a hold rating in a research note on Wednesday, July 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Lexicon Pharmaceuticals has a consensus rating of Hold and a consensus price target of $16.38.

Shares of Lexicon Pharmaceuticals stock opened at $5.28 on Friday. The company’s fifty day simple moving average is $5.89. The company has a market cap of $561.12 million, a PE ratio of -4.63 and a beta of 0.84. Lexicon Pharmaceuticals has a 52 week low of $4.25 and a 52 week high of $13.13.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $9.20 million for the quarter, compared to the consensus estimate of $13.26 million. The business’s revenue was down 63.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.40) EPS. As a group, research analysts forecast that Lexicon Pharmaceuticals will post -0.47 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in LXRX. BNP Paribas Arbitrage SA boosted its stake in Lexicon Pharmaceuticals by 940.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 8,979 shares during the period. Wealth & Pension Services Group Inc. acquired a new position in Lexicon Pharmaceuticals in the 1st quarter worth $60,000. Paloma Partners Management Co acquired a new position in Lexicon Pharmaceuticals in the 4th quarter worth $73,000. CWM Advisors LLC boosted its stake in Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 3,030 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 11,862 shares during the period. 98.27% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: What are the FAANG Stocks?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.